Timing of alemtuzumab with respect to day of bone marrow
infusion and its effects upon engraftment and graft-versus-host disease
in patients with hemoglobinopathy: A single institutional study.
Indira Sahdev, M.D1*, Joel Brochstein,
MD1, Nan Werther, NP1, Jessica
Stiles, NP1
1 Division of Pediatric Hematology/Oncology and Stem
Cell Transplantation, Department of Pediatrics, Cohen Children’s Medical
Center of New York
*Corresponding Author: Indira Sahdev, MD
Division of Pediatric Hematology/ Oncology/Stem Cell Transplantation
Department of Pediatrics, Cohen Children’s Medical Center of New York
269-01, 76th. Ave. New Hyde Park, NY-11040
Tel: 718-470-3460, Email:
isahdev@northwell.edu.
Abstract word count: 250
Text word count: 2558
Number of tables: 2
Brief running title: Timing of alemtuzumab administration as a
conditioning regimen and impact on outcome
Key words: Hemoglobinopathies, Allogeneic Hematopoietic Stem Cell
Transplantation, Alemtuzumab, Graft failure, Graft- versus- host disease